US biotech major Biogen (Nasdaq: BIIB) reported stronger-than-expected earnings for the first quarter of 2025, helped by ...

Ionis Pharmaceuticals beat Q1 earnings and revenue estimates, raising its 2025 outlook, and reported strong sales from new ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the first quarter ended March ...

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

and Tysabri (natalizumab), as well as blockbuster spinal muscular atrophy therapy Spinraza (nusinersen). Biogen will retain its commercial rights to the biosimilars already brought to market ...

Evrysdi is the third treatment approved for SMA, an ultra-rare muscle wasting disease that can begin in early childhood, after Biogen’s Spinraza (nusinersen) and Novartis’ Zolgensma ...

Use of Evidence-Based Vital Signs in Pediatric Early Warning Score to Predict Clinical Deterioration on Acute Care Units.

Liver damage related to Zolgensma gene therapy usually resolves within a few months of treatment, a study found.

Researchers studied 118 SMA type 2 patients and saw their RULM scores stayed higher than expected had their disease kept its ...